» Articles » PMID: 30343312

Impact of a Multifaceted Prevention Program on Ventilator-associated Pneumonia Including Selective Oropharyngeal Decontamination

Overview
Specialty Critical Care
Date 2018 Oct 22
PMID 30343312
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We describe the impact of a multifaceted program for decreasing ventilator-associated pneumonia (VAP) after implementing nine preventive measures, including selective oropharyngeal decontamination (SOD).

Methods: We compared VAP rates during an 8-month pre-intervention period, a 12-month intervention period, and an 11-month post-intervention period in a cohort of patients who received mechanical ventilation (MV) for > 48 h. The primary objective was to assess the effect on first VAP occurrence, using a Cox cause-specific proportional hazards model. Secondary objectives included the impact on emergence of antimicrobial resistance, antibiotic consumption, duration of MV, and ICU mortality.

Results: Pre-intervention, intervention and post-intervention VAP rates were 24.0, 11.0 and 3.9 VAP episodes per 1000 ventilation-days, respectively. VAP rates decreased by 56% [hazard ratio (HR) 0.44, 95% CI 0.29-0.65; P < 0.001] in the intervention and by 85% (HR 0.15, 95% CI 0.08-0.27; P < 0.001) in the post-intervention periods. During the intervention period, VAP rates decreased by 42% (HR 0.58, 95% CI 0.38-0.87; P < 0.001) after implementation of eight preventive measures without SOD, and by 70% after adding SOD (HR 0.30, 95% CI 0.13-0.72; P < 0.001) compared to the pre-intervention period. The incidence density of intrinsically resistant bacteria (to colistin or tobramycin) did not increase. We documented a significant reduction of days of therapy per 1000 patient-days of broad-spectrum antibiotic used to treat lower respiratory tract infection (P < 0.028), median duration of MV (from 7.1 to 6.4 days; P < 0.003) and ICU mortality (from 16.2 to 13.5%; P < 0.049) for patients ventilated > 48 h between the pre- and post-intervention periods.

Conclusions: Our preventive program produced a sustained decrease in VAP incidence. SOD provides an additive value.

Citing Articles

A multimedia tool for infection prevention and control practices in the intensive care unit: a participatory interventional before-after study.

Bijarania S, Kaur R, Biswal M, Maheshwar S, Ganesan R, Puri G Infect Prev Pract. 2025; 7(1):100423.

PMID: 39807390 PMC: 11728882. DOI: 10.1016/j.infpip.2024.100423.


Rebound Inverts the Bacteremia Prevention Effect of Antibiotic Based Decontamination Interventions in ICU Cohorts with Prolonged Length of Stay.

Hurley J Antibiotics (Basel). 2024; 13(4).

PMID: 38666992 PMC: 11047347. DOI: 10.3390/antibiotics13040316.


Molecular mechanism of honeysuckle + forsythia in treatment of acute lung injury based on network pharmacology.

Wen X, Cheng M, Song Z, Hu J, Liang X, Lang W Biomed Rep. 2024; 20(2):32.

PMID: 38273899 PMC: 10809323. DOI: 10.3892/br.2024.1720.


Prevention of ventilator-associated pneumonia through care bundles: A systematic review and meta-analysis.

Martinez-Reviejo R, Tejada S, Jansson M, Ruiz-Spinelli A, Ramirez-Estrada S, Ege D J Intensive Med. 2023; 3(4):352-364.

PMID: 38028633 PMC: 10658042. DOI: 10.1016/j.jointm.2023.04.004.


The ongoing challenge of ventilator-associated pneumonia: epidemiology, prevention, and risk factors for mortality in a secondary care hospital intensive care unit.

Semet C Infect Prev Pract. 2023; 5(4):100320.

PMID: 38028359 PMC: 10663678. DOI: 10.1016/j.infpip.2023.100320.


References
1.
Li J, Xie D, Li A, Yue J . Oral topical decontamination for preventing ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials. J Hosp Infect. 2013; 84(4):283-93. DOI: 10.1016/j.jhin.2013.04.012. View

2.
Alvarez-Lerma F, Palomar-Martinez M, Sanchez-Garcia M, Martinez-Alonso M, Alvarez-Rodriguez J, Lorente L . Prevention of Ventilator-Associated Pneumonia: The Multimodal Approach of the Spanish ICU "Pneumonia Zero" Program. Crit Care Med. 2017; 46(2):181-188. PMC: 5770104. DOI: 10.1097/CCM.0000000000002736. View

3.
Klompas M . Ventilator-associated pneumonia: is zero possible?. Clin Infect Dis. 2010; 51(10):1123-6. DOI: 10.1086/656738. View

4.
Barbier F, Andremont A, Wolff M, Bouadma L . Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med. 2013; 19(3):216-28. DOI: 10.1097/MCP.0b013e32835f27be. View

5.
Bouadma L, Mourvillier B, Deiler V, Le Corre B, Lolom I, Regnier B . A multifaceted program to prevent ventilator-associated pneumonia: impact on compliance with preventive measures. Crit Care Med. 2010; 38(3):789-96. DOI: 10.1097/CCM.0b013e3181ce21af. View